Literature DB >> 24562637

Impact of atrial remodeling on the outcome of radiofrequency catheter ablation of paroxysmal atrial fibrillation.

Koichiro Ejima1, Ken Kato, Kotaro Arai, Keiko Fukushima, Noritoshi Fukushima, Tsuyoshi Suzuki, Kentaro Yoshida, Toshiaki Nuki, Shoko Uematsu, Hiromi Hoshi, Tetsuyuki Manaka, Kyomi Ashihara, Morio Shoda, Nobuhisa Hagiwara.   

Abstract

BACKGROUND: Both the left atrial volume index (LAVI) and estimated total atrial conduction time measured using tissue Doppler imaging of the atria (PA-TDI duration) are echocardiographic parameters reflecting atrial remodeling. We investigated their prognostic value for atrial tachyarrhythmia (AF/AT) recurrence after radiofrequency catheter ablation (RFCA) of paroxysmal atrial fibrillation (PAF). METHODS AND
RESULTS: We analyzed the data for 100 consecutive patients with drug-refractory PAF who underwent RFCA. The correlation between the LAVI and PA-TDI was extremely weak (r=0.26, P<0.01). We categorized the patients into 4 groups based on the median LAVI and PA-TDI duration: group 1 (LAVI <29ml/m(2)/PA-TDI duration <143ms), group 2 (LAVI ≥29ml/m(2)/PA-TDI duration <143ms), group 3 (LAVI <29ml/m(2)/PA-TDI duration ≥143ms), and group 4 (LAVI ≥29ml/m(2)/PA-TDI duration ≥143ms). With a mean follow-up of 20.2±8.9 months after a single RFCA procedure, 60 patients (60%) were in sinus rhythm without any antiarrhythmic drugs. Multivariate analysis using a Cox proportional hazards model demonstrated that the group was an independent predictor of AF/AT recurrence after RFCA (P=0.0017). The patients in groups 2, 3, and 4 had a 4.0-fold (P=0.048), 6.8-fold (P=0.0034) and 10.9-fold (P=0.0001) increase, respectively, in the probability of recurrent AF/AT as compared with group 1.
CONCLUSIONS: Preprocedural echocardiographic estimation of atrial remodeling was a useful predictor of AF/AT recurrence following a single RFCA of PAF.

Entities:  

Mesh:

Year:  2014        PMID: 24562637     DOI: 10.1253/circj.cj-13-1391

Source DB:  PubMed          Journal:  Circ J        ISSN: 1346-9843            Impact factor:   2.993


  10 in total

1.  Catheter ablation of atrial fibrillation in patients with severely impaired left ventricular systolic function.

Authors:  Ken Kato; Koichiro Ejima; Noritoshi Fukushima; Makoto Ishizawa; Osamu Wakisaka; Ryuta Henmi; Kentaro Yoshida; Toshiaki Nuki; Kotaro Arai; Bun Yashiro; Tetsuyuki Manaka; Kyomi Ashihara; Morio Shoda; Nobuhisa Hagiwara
Journal:  Heart Vessels       Date:  2015-01-30       Impact factor: 2.037

Review 2.  Immunopathogenesis and biomarkers of recurrent atrial fibrillation following ablation therapy in patients with preexisting atrial fibrillation.

Authors:  John H Rosenberg; John H Werner; Gilman D Plitt; Victoria V Noble; Jordan T Spring; Brooke A Stephens; Aleem Siddique; Helenmari L Merritt-Genore; Michael J Moulton; Devendra K Agrawal
Journal:  Expert Rev Cardiovasc Ther       Date:  2018-12-29

3.  Echocardiographic assessment in patients with atrial fibrillation (AF) and normal systolic left ventricular function before and after catheter ablation: If AF begets AF, does pulmonary vein isolation terminate the vicious circle?

Authors:  Aleksandra Liżewska-Springer; Alicja Dąbrowska-Kugacka; Ewa Lewicka; Tomasz Królak; Łukasz Drelich; Dariusz Kozłowski; Grzegorz Raczak
Journal:  Cardiol J       Date:  2019-01-31       Impact factor: 2.737

4.  Investigation of the atrial conduction time measured by tissue Doppler imaging at the left atrial appendage and the actual electrical conduction time: consideration of left atrial remodeling in atrial fibrillation patients.

Authors:  Yuichi Hori; Shiro Nakahara; Naofumi Anjo; Ayako Nakagawa; Naoki Nishiyama; Kouta Yamada; Akiko Hayashi; Takaaki Komatsu; Sayuki Kobayashi; Yoshihiko Sakai; Isao Taguchi
Journal:  J Interv Card Electrophysiol       Date:  2016-09-22       Impact factor: 1.900

5.  Impact of a prolonged interatrial conduction time for predicting the recurrence of atrial fibrillation after circumferential pulmonary vein isolation of persistent atrial fibrillation.

Authors:  Satoshi Higuchi; Koichiro Ejima; Morio Shoda; Eri Yamamoto; Yuji Iwanami; Daigo Yagishita; Nobuhisa Hagiwara
Journal:  Heart Vessels       Date:  2018-10-05       Impact factor: 2.037

6.  Topographic variability of the left atrium and pulmonary veins assessed by 3D-CT predicts the recurrence of atrial fibrillation after catheter ablation.

Authors:  Kunihiko Kiuchi; Akihiro Yoshida; Asumi Takei; Koji Fukuzawa; Mitsuaki Itoh; Kimitake Imamura; Ryudo Fujiwara; Atsushi Suzuki; Tomoyuki Nakanishi; Soichiro Yamashita; Ken-Ichi Hirata; Gaku Kanda; Katsunori Okajima; Akira Shimane; Shinichiro Yamada; Yasuyo Taniguchi; Yoshinori Yasaka; Hiroya Kawai
Journal:  J Arrhythm       Date:  2015-04-25

7.  Decreased estimated glomerular filtration rate predicts long-term recurrence after catheter ablation of atrial fibrillation in mild to moderate renal insufficiency.

Authors:  Jing Zheng; Deling Zu; Keyun Cheng; Yunlong Xia; Yingxue Dong; Zhenyan Gao
Journal:  BMC Cardiovasc Disord       Date:  2021-10-21       Impact factor: 2.298

Review 8.  Echocardiography-derived total atrial conduction time (PA-TDI duration): risk stratification and guidance in atrial fibrillation management.

Authors:  Patrick Müller; Bob Weijs; Nadine M A A Bemelmans; Andreas Mügge; Lars Eckardt; Harry J G M Crijns; Jeroen J Bax; Dominik Linz; Dennis W den Uijl
Journal:  Clin Res Cardiol       Date:  2021-08-28       Impact factor: 5.460

9.  Predictive value of various Doppler-derived parameters of atrial conduction time for successful atrial fibrillation ablation.

Authors:  Miriam Shanks; Lucas Valtuille; Jonathan B Choy; Harald Becher
Journal:  Echo Res Pract       Date:  2015-10-21

10.  Fibrinolytic Deficit and Platelet Activation in Atrial Fibrillation and Their Postablation Modulation.

Authors:  Abigail Otto; Jawed Fareed; Jeffrey Liles; Stephen Statz; Amanda Walborn; Timothy Rowe; Sallu Jabati; Debra Hoppensteadt; Mushabar A Syed
Journal:  Clin Appl Thromb Hemost       Date:  2018-01-28       Impact factor: 2.389

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.